A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

NCT ID: NCT02718131

Last Updated: 2021-10-27

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-01
• Study Completion Date: 2020-06-01

Brief Summary

The current study proposes adding BMP-2 (INFUSE), an anabolic agent, at the surgical site of TPA (tibial pseudarthrosis) repair in children with NF1, compared to a control group of patients treated surgically without BMP-2. The following Specific Aims will be addressed: 1) to determine if use of an osteogenic agent (BMP-2) at the time of surgical repair of TPA in NF1 patients will result in improved bone healing; 2) to document safety of BMP-2 in a pediatric NF1 population; and 3) to collect, process, and preserve biologic specimens at the time of surgery for future studies.

Detailed Description

A randomized study will be performed by a multi-center group of the NF Consortium. A total of 54 patients will be randomized for treatment with or without INFUSE Bone Graft at the time of surgical repair. For all patients, a standard surgical procedure will be used, including: resection of pseudarthrosis tissue; placement of a rigid intramedullary rod; and placement of autogenous bone graft from iliac crest. For patients in the BMP group, the INFUSE device containing BMP-2 will in addition be applied intraoperatively to the osteotomy site. Fracture union will be determined by scoring of radiographs (RUST score) for cortical bone fusion and callus formation at the osteotomy site. RUST score at 12 months post-surgery will be the primary outcome measure to determine efficacy. Secondary measures will include determination of time to healing (months); quality of life measures; functional walking measures; and incidence of refracture after surgery. This study, once successfully completed, will determine if use of INFUSE Bone Graft improves healing of tibial pseudarthrosis in NF1 and will document safety issues. Regardless of results, the better performing of the two groups (control or BMP) will be able to serve as a much-needed control arm for future studies of additional targeted therapeutic agents for NF1-related bone disease. An international working group of orthopaedic surgeons and NF specialists has been formed and is committed to successful completion of this trial.

Conditions

NF1; Congenital Pseudarthrosis of Tibia

Keywords

Tibial Pseudarthrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

INFUSE Bone Graft (BMP-2)

Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.

Group Type: ACTIVE_COMPARATOR

INFUSE Bone Graft (BMP-2)

Intervention Type: DEVICE

The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.

Control Group

Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.

Group Type: PLACEBO_COMPARATOR

Control Group

Intervention Type: PROCEDURE

The control group will receive the standard surgical protocol, without addition of the INFUSE device.

Interventions

INFUSE Bone Graft (BMP-2)

The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.

Intervention Type: DEVICE

Control Group

The control group will receive the standard surgical protocol, without addition of the INFUSE device.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Diagnosis of NF1 using the NIH Consensus Conference criteria. In addition to tibial pseudarthrosis, one or more of the following diagnostic criteria for NF1 must be present:
• Six or more cafe'-au-lait spots (≥ 0.5cm prepubertal; ≥ 1.5cm postpubertal)
• Freckling in the axilla or groin Optic pathway glioma
• Two or more iris Lisch nodules
• Two or more neurofibromas or one plexiform neurofibroma
• A first-degree relative with NF1
• Patients must have tibial pseudarthrosis that has the potential to cause significant morbidity. Radiographic findings (AP & lateral leg radiographs) must support the diagnosis of tibial pseudarthrosis with chronic non-union.
• Age between 2 years and 18 years of age at time of study entry.
• Performance Level: Karnofsky ≥ 50 percent for patients > 10 years of age and Lansky ≥ 50 percent for patients or ≤ 10 years of age.

Prior Therapy:

• Patients who have undergone 1 previous surgery for tibial pseudarthrosis repair will be eligible to enter the study if they have refracture.
• Use of BMP-2 in the prior surgery is permitted, however patients with prior exposure must be screened for antibodies to BMP-2, bovine collagen, and rhBMP-2 neutralizing antibodies.
• Prior use of BMP-2 is allowed but will be recorded as a possible compounding factor.
• Patients who have had 2 or more prior surgeries for pseudarthrosis repair are ineligible

Absence of Tumors:

• Patients must undergo thorough physical examination of the leg undergoing surgery. If physical exam is equivocal for presence of tumors, then a normal MRI of the lower extremity will be required before eligibility is met.
• If there is evidence of plexiform neurofibroma or nodular neurofibroma of > 3 cm diameter on the ipsilateral leg, then they are ineligible for the study.
• Organ Function Requirements
• Adequate bone marrow function defined as:

• Absolute neutrophil count (ANC) > 1500/
• µl Platelet count > 100,000/
• µl Hemoglobin ≥ 10.0 gm/dL

Adequate renal function defined as:

• maximum serum creatinine of 1.5 mg/dL OR
• a creatinine clearance≥70ml/min/1.73m2.

Adequate renal function defined as:

• maximum serum creatinine of 1.5 mg/dL OR
• a creatinine clearance ≥ 70ml/min/1.73m2.

Adequate liver function defined as:

• Total bilirubin < 1.5 X upper limit of normal for age, and SGPT (serum glutamic pyruvic transaminase, ALT) < 2 X upper limit of normal for age
• Serum Vitamin D level ≥ 10 ng/ml

Exclusion Criteria

• Lack of documentation for a diagnosis of NF1
• Tibial fracture without evidence of pseudarthrosis or tibial dysplasia
• Tibial dysplasia/bowing without fracture or pseudarthrosis
• Plexiform neurofibroma of any size, or nodular neurofibroma of > 3 cm diameter involving the ipsilateral leg, including the hip
• If presence of plexiform is suspected but not certain on physical exam, MRI of the leg may be indicated to rule this out.
• History of MPNST (malignant peripheral nerve sheath tumor) or any malignancy other than asymptomatic and stable optic nerve glioma
• Optic nerve glioma that has resulted in precocious puberty or visual impairment of any degree
• Visual impairment from any cause
• Precocious puberty from any cause
• Hypertension other than mild essential hypertension controlled with medication
• Metastatic disease of any kind
• Inadequate neurovascular status in the involved limb that may jeopardize healing
• Active or known prior infection at the pseudarthrosis site
• Active systemic infection
• Other injury or condition that prevents ambulation or completion of study assessments
• Two or more prior surgeries for tibial pseudarthrosis
• Bilateral tibial dysplasia
• Selection of a surgical approach that does not include prescribed surgical intervention, which must include removal of pseudarthrosis tissue, placement of an intramedullary rod using the Williams approach, and autogenous bone graft from the iliac crest distributed at the osteotomy site
• Normal ipsilateral fibula without planned fibular osteotomy at time of surgery
• Allergy to bone morphogenetic protein
• Allergy to bovine collagen products
• Positive antibody titers to BMP-2, bovine collagen, or BMP-2 neutralizing antibodies prior to surgery
• History of using any of the following medications, regardless of dose, for at least 1 month, within 3 months of enrollment: Anabolic agents, Glucocorticoids (does not include inhaled glucocorticoids), Growth hormone, Parathyroid hormone (PTH)
• Need for postoperative medications that could interfere with bone healing of the implant, such as steroids, (but not including low-dose aspirin or routine perioperative anti-inflammatory drugs)
• Untreated endocrine abnormality, such as hypothyroidism, parathyroid hormone disorder
• Severe Vitamin D deficiency with serum 25-OH (hydroxy) Vitamin D < 10 ng/ml (25 nmol/l) Patients with Vitamin D levels < 10 ng/ml may be treated with Vitamin D and reconsidered for enrollment when levels are sufficient
• Females who are sexually active without use of effective contraception
• Females who are pregnant or breastfeeding

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Children's Tumor Foundation

OTHER

Sponsor Role: collaborator

Medtronic

INDUSTRY

Sponsor Role: collaborator

University of Alabama at Birmingham

OTHER

Sponsor Role: lead

Responsible Party

Bruce Korf, MD

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Bruce R. Korf, MD, PhD

Role: STUDY_CHAIR

Univ. of Alabama at Birmingham

Locations

The University of Alabama at Birmingham

Birmingham, Alabama, United States

Children's Hospital Los Angeles

Los Angeles, California, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

Children's Lurie Hospital

Chicago, Illinois, United States

University of Chicago

Chicago, Illinois, United States

Indiana Unversity

Indianapolis, Indiana, United States

Johns Hopkins

Baltimore, Maryland, United States

Children' Hospital Boston and Massachusetts General Hospital

Boston, Massachusetts, United States

Children' Hospital Boston

Boston, Massachusetts, United States

Washington University in St. Louis

St Louis, Missouri, United States

New York University Medical Center

New York, New York, United States

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Texas Scottish Rite Hospital for Children

Dallas, Texas, United States

University of Utah

Salt Lake City, Utah, United States

The Children's Hospital at Westmead

Westmead, New South Wales, Australia

Countries

United States; Australia

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

W81XWH-12-1-0155

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

G140004

Identifier Type: OTHER

Identifier Source: secondary_id

507821

Identifier Type: OTHER

Identifier Source: secondary_id

NF107

Identifier Type: -

Identifier Source: org_study_id